摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-氟-2-硝基-苯乙酸 | 872141-25-8

中文名称
3-氟-2-硝基-苯乙酸
中文别名
2-(3-氟-2-硝基苯基)乙酸;2-(2-硝基-3-氟苯基)乙酸
英文名称
2-(3-fluoro-2-nitrophenyl)acetic acid
英文别名
——
3-氟-2-硝基-苯乙酸化学式
CAS
872141-25-8
化学式
C8H6FNO4
mdl
——
分子量
199.138
InChiKey
ZHQHUGDDYSPNTM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    14
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    83.1
  • 氢给体数:
    1
  • 氢受体数:
    5

安全信息

  • 海关编码:
    2916399090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335

SDS

SDS:95748a0a68d6bc140ef41a53ec441734
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: (3-Fluoro-2-nitrophenyl)acetic acid
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: (3-Fluoro-2-nitrophenyl)acetic acid
CAS number: 872141-25-8

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H6FNO4
Molecular weight: 199.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-氟-2-硝基-苯乙酸 在 palladium 10% on activated carbon 、 5% rhodium-on-charcoal 三甲基氯硅烷氢气N,N-二异丙基乙胺N,N'-羰基二咪唑 作用下, 以 四氢呋喃甲醇N,N-二甲基甲酰胺 为溶剂, 20.0~100.0 ℃ 、300.01 kPa 条件下, 反应 6.5h, 生成 3-{1-[6-(3,4-dimethyl-2-oxo-2,3-dihydro-benzoxazole-6-carbonyl)-pyrimidin-4-yl]-piperidin-4-yl}-9-fluoro-1,3,4,5-tetrahydro-benzo[d][1,3]diazepin-2-one
    参考文献:
    名称:
    CGRP ANTAGONISTS
    摘要:
    本发明涉及一般式I的新的CGRP拮抗剂,其中U、V、X、Y、R1、R2和R3如下所述定义,其互变异构体、同分异构体、对映异构体、水合物、混合物及其盐和盐的水合物,特别是其与无机或有机酸或碱的生理上可接受的盐,含有这些化合物的药物组合物,其用途以及制备它们的过程。
    公开号:
    US20110059954A1
  • 作为产物:
    描述:
    2-(3-氟-2-硝基苯基)丙二酸二甲酯盐酸 作用下, 反应 24.0h, 以54%的产率得到3-氟-2-硝基-苯乙酸
    参考文献:
    名称:
    设计,合成和合成新的吡咯-羟吲哚孕酮受体调节剂导致5-(7-氟-3,3-二甲基-2-氧-2-3-二氢-1H-吲哚-5-基)-1-甲基-1H-吡咯-2-c芳腈(WAY-255348)。
    摘要:
    我们继续探索3,3-二烷基-5-芳基吲哚系列孕酮受体(PR)调节剂,以寻找用于女性保健的新药物:避孕,肌瘤,子宫内膜异位症和某些乳腺癌。先前,我们报道了该模板和相关模板的微妙结构变化在激动剂和拮抗剂特性之间产生了功能转换(Fensome等,Biorg。Med。Chem。Lett。2002,12,3487; 2003,13,1317)。我们在本文中报道了5-(2-氧代吲哚-5-基)-1 H-吡咯-2-腈类化合物中的新功能开关。我们发现3,3-二烷基取代基的大小对于控制功能响应很重要。因此,小的基团(二甲基)提供有效的PR拮抗剂,而较大的基团(螺环己基)是PR激动剂。
    DOI:
    10.1021/jm701080t
点击查看最新优质反应信息

文献信息

  • CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS
    申请人:Chaturvedula Prasad V.
    公开号:US20070259851A1
    公开(公告)日:2007-11-08
    The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
    本发明包括受约束的双环和三环CGRP受体拮抗剂,识别它们的方法,包含它们的药物组合物,以及它们在治疗偏头痛和其他头痛、神经源性血管扩张、神经性炎症、热损伤、循环性休克、与更年期相关的潮红、气道炎症性疾病(如哮喘和慢性阻塞性肺病(COPD))中的用途,以及其他可以通过CGRP受体拮抗剂治疗的疾病。
  • [EN] AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF<br/>[FR] DÉRIVÉS D'AMINOMÉTHYL-BIARYL EN TANT QU'INHIBITEURS DU FACTEUR D DU COMPLÉMENT ET LEURS UTILISATIONS
    申请人:NOVARTIS AG
    公开号:WO2015009977A1
    公开(公告)日:2015-01-22
    The present invention provides a compound of formula (I), a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    本发明提供了一种公式(I)的化合物,一种制造本发明化合物的方法及其治疗用途。本发明进一步提供了一种药物活性剂的组合物和一种药物组合物。
  • Concise Synthesis of Furo[2,3-b]indolines via [3,3]-Sigmatropic Rearrangement of N-Alkenyloxyindoles
    作者:Laura L. Anderson、Michael Shevlin、Neil A. Strotman
    DOI:10.1055/s-0040-1707250
    日期:2021.1
    concise new synthetic route to furo[2,3-b]indolines has been developed by taking advantage of the reactivity of N-alkenyloxyindole intermediates. These compounds spontaneously undergo [3,3]-sigmatropic rearrangement followed by cyclization to form hemiaminals as single diastereomers. Tin-promoted N-hydroxyindole formation followed by conjugate addition to activated alkynes provides simple and modular
    利用 N-链烯氧基吲哚中间体的反应性,开发了一种简洁的呋喃 [2,3-b] 吲哚啉合成路线。这些化合物自发地经历 [3,3]-σ 重排,然后环化形成作为单一非对映异构体的半缩酸。促进的 N-羟基吲哚形成,然后与活化炔烃的共轭加成提供了对各种 N-烯氧基吲哚及其相应呋喃 [2,3-b] 吲哚啉的简单和模块化的访问。微型高通量实验用于促进对这种转化的范围和耐受性的研究,并且还评估了对 N-羟基吲哚与卤代芳烃的亲核芳香取代和重排的相关研究。
  • NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS
    申请人:GALDERMA RESEARCH & DEVELOPMENT
    公开号:US20180050992A1
    公开(公告)日:2018-02-22
    The invention relates to novel heterocyclic compounds of general formula (I), as well as their pharmaceutically acceptable salts, and their enantiomers. The invention also relates to the use thereof as a medicinal product, preferably in the prevention and/or treatment of inflammatory diseases with a neurogenic component or use thereof as a cosmetic. The compounds of the present invention act as antagonists of the CGRP-R receptor.
    这项发明涉及一般式(I)的新型杂环化合物,以及它们的药用盐和对映体。该发明还涉及将其用作药物产品,优选用于预防和/或治疗具有神经源性成分的炎症性疾病,或将其用作化妆品。本发明的化合物作为CGRP-R受体的拮抗剂。
  • A safe and selective method for reduction of 2-nitrophenylacetic acid systems to N-aryl hydroxamic acids using continuous flow hydrogenation
    作者:Ogar Ichire、Petra Jans、Galina Parfenov、Amy B. Dounay
    DOI:10.1016/j.tetlet.2017.01.008
    日期:2017.2
    The cyclic hydroxamic acid functional group is critical to the biological activity of numerous natural products and drug candidates. Efficient, reliable, and green synthetic methods to produce cyclic hydroxamic acids are needed. Herein, flow hydrogenation has been explored as a novel approach toward achieving the selective partial reduction of 2-nitrophenylacetic acid to 1-hydroxyindolin-2-one. The
    环状异羟酸官能团对于众多天然产物和候选药物的生物活性至关重要。需要有效,可靠和绿色的合成方法来生产环状异羟酸。在本文中,已经探索了流动氢化作为实现2-硝基苯乙酸选择性部分还原为1-羟基吲哚-2-酮的新方法。双齿配体1,10-咯啉已被确定为在Pt / C催化过程中调节产物选择性的独特抑制剂。根据新优化的反应条件下,有针对性的hydroxami Ç产生以高选择性(49:1)在酸的副产物的内酰胺。对于多种2-硝基苯乙酸生物证明了反应范围。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫